The Old Relationship Between the Use of Iron Sailings to Biochemical Bone Profiles in Thalassemia Patients

Oct 13, 2025 by leolavanderia.com.br 33 views

The Old Relationship Between the Use of Iron Sailings to Biochemical Bone Profiles in Thalassemia Patients

Introduction

Thalassemia is a genetic hematological disorder that requires a lifetime blood transfusion. Giving prolonged blood transfusion can cause a buildup of iron in the body, which has the potential to cause various health problems, including heart disease and endocrine abnormalities that can affect bone profiles. A study conducted in Mosul shows the relationship between the duration of use of iron sailing agents with bone biochemical profiles, especially alkaline phosphatase levels. In this article, we will discuss the long relationship of use of iron pinstation to biochemical bone profiles in thalassemia patients.

The Importance of Understanding the Relationship Between Iron Sailings and Bone Profiles

Thalassemia patients require a lifetime of blood transfusions, which can lead to a buildup of iron in the body. This can cause various health problems, including heart disease and endocrine abnormalities that can affect bone profiles. Therefore, it is essential to understand the relationship between the use of iron sailings and bone biochemical profiles in thalassemia patients. This knowledge can help healthcare providers to develop effective prevention strategies to maintain the quality of life of patients.

Research Purposes

This study aims to determine the effect of the duration of use of iron sailing agents on bone biochemical profiles in thalassemia patients. This research is important to determine the long-term impact of therapy given to thalassemia patients, especially related to their bone health. The study also aims to identify the correlation between the duration of use of iron sailing agents and bone biochemical profiles, including calcium, phosphorus, alkaline phosphatase, and serum albumin levels.

Research Methods

This study was conducted with a cross-sectional design at Adam Malik Hajj Hospital and Sari Mutiara Hospital Medan, taking place from July to September 2015. All research subjects were measured by bone biochemical profiles. The data obtained was then analyzed using the Spearman correlation test with a P value of less than 0.05 as a criterion for statistical significance.

Research Result

A total of 33 children with Thalassemia participated in this study. The average age of the subject is 10 years (SD: 3,90), and the average length of use of iron sailors is 6 months (SD: 3,42). The results of bone profile measurements show that the average calcium level is 9 mg/dl (SD: 0.86), phosphorus 4.6 mg/dl (SD: 0.66), alkaline phosphatase 293.2 IU/L (SD: 157.40), and serum albumin 3.8 g/dl (SD: 0.50). The Spearman correlation test shows the absence of a significant correlation between the length of use of iron sailing agents and bone biochemical profiles (P:> 0.05).

Correlation for each parameter between the duration of the use of iron sailing agents and bone profiles is as follows:

Calcium (R = 0.196): This correlation shows a weak relationship between the duration of use of iron sailing agents and calcium levels.
Phosphorus (R = -0.219): This correlation shows a weak negative relationship between the duration of use of iron sailing agents and phosphorus levels.
Alkaline Phosphatase (r = 0.251): This correlation shows a weak positive relationship between the duration of use of iron sailing agents and alkaline phosphatase levels.
Albumin (R = 0.155): This correlation shows a weak positive relationship between the duration of use of iron sailing agents and albumin levels.

Conclusion

Long-term use of iron sailings agents has a weak correlation with bone biochemical profiles in thalassemia patients. This shows that although iron sail therapy is important for managing iron buildup, its impact on bone health may be insignificant. Therefore, there needs to be further monitoring of Thalassemia patients, especially those who use iron sailors agents for a long time, to understand more about their bone health and identify more effective prevention strategies to maintain the quality of life of patients.

Recommendations

Based on the findings of this study, the following recommendations are made:

Further Research: Further research is needed to understand the relationship between the use of iron sailings and bone biochemical profiles in thalassemia patients.
Monitoring: Thalassemia patients, especially those who use iron sailors agents for a long time, should be monitored regularly to understand more about their bone health.
Prevention Strategies: Effective prevention strategies should be developed to maintain the quality of life of thalassemia patients.

Limitations

This study has several limitations, including:

Small Sample Size: The sample size of this study is small, which may limit the generalizability of the findings.
Cross-Sectional Design: The study used a cross-sectional design, which may not be able to capture the longitudinal effects of iron sail therapy on bone health.

Future Directions

Future studies should aim to:

Increase Sample Size: Increase the sample size to improve the generalizability of the findings.
Use Longitudinal Design: Use a longitudinal design to capture the longitudinal effects of iron sail therapy on bone health.
Investigate Other Factors: Investigate other factors that may affect the relationship between iron sail therapy and bone health, such as age, sex, and genetic factors.
Q&A: The Old Relationship Between the Use of Iron Sailings to Biochemical Bone Profiles in Thalassemia Patients

Introduction

In our previous article, we discussed the long relationship of use of iron pinstation to biochemical bone profiles in thalassemia patients. In this article, we will answer some of the most frequently asked questions about the study and its findings.

Q: What is thalassemia?

A: Thalassemia is a genetic hematological disorder that requires a lifetime blood transfusion. Giving prolonged blood transfusion can cause a buildup of iron in the body, which has the potential to cause various health problems, including heart disease and endocrine abnormalities that can affect bone profiles.

Q: What is the purpose of the study?

A: The purpose of the study is to determine the effect of the duration of use of iron sailing agents on bone biochemical profiles in thalassemia patients. This research is important to determine the long-term impact of therapy given to thalassemia patients, especially related to their bone health.

Q: What were the research methods used in the study?

A: The study was conducted with a cross-sectional design at Adam Malik Hajj Hospital and Sari Mutiara Hospital Medan, taking place from July to September 2015. All research subjects were measured by bone biochemical profiles. The data obtained was then analyzed using the Spearman correlation test with a P value of less than 0.05 as a criterion for statistical significance.

Q: What were the results of the study?

A: The results of the study show that the average calcium level is 9 mg/dl (SD: 0.86), phosphorus 4.6 mg/dl (SD: 0.66), alkaline phosphatase 293.2 IU/L (SD: 157.40), and serum albumin 3.8 g/dl (SD: 0.50). The Spearman correlation test shows the absence of a significant correlation between the length of use of iron sailing agents and bone biochemical profiles (P:> 0.05).

Q: What does the correlation between iron sailings and bone profiles mean?

A: The correlation between iron sailings and bone profiles shows a weak relationship between the duration of use of iron sailing agents and bone biochemical profiles. This means that although iron sail therapy is important for managing iron buildup, its impact on bone health may be insignificant.

Q: What are the implications of the study's findings?

A: The study's findings have several implications for the management of thalassemia patients. Firstly, it highlights the need for further monitoring of thalassemia patients, especially those who use iron sailors agents for a long time, to understand more about their bone health. Secondly, it suggests that effective prevention strategies should be developed to maintain the quality of life of thalassemia patients.

Q: What are the limitations of the study?

A: The study has several limitations, including a small sample size and a cross-sectional design. These limitations may limit the generalizability of the findings and the ability to capture the longitudinal effects of iron sail therapy on bone health.

Q: What are the future directions for research?

A: Future studies should aim to increase the sample size, use a longitudinal design, and investigate other factors that may affect the relationship between iron sail therapy and bone health, such as age, sex, and genetic factors.

Q: What can thalassemia patients do to maintain their bone health?

A: Thalassemia patients can take several steps to maintain their bone health, including:

Regular monitoring: Regular monitoring of bone health by healthcare providers is essential to detect any abnormalities early.
Dietary changes: Dietary changes, such as increasing calcium and vitamin D intake, can help maintain bone health.
Exercise: Regular exercise, such as weight-bearing exercises, can help maintain bone density.
Medication: Medication, such as bisphosphonates, can help maintain bone health in thalassemia patients.

Conclusion

In conclusion, the study's findings highlight the need for further research into the relationship between iron sail therapy and bone health in thalassemia patients. Thalassemia patients can take several steps to maintain their bone health, including regular monitoring, dietary changes, exercise, and medication.